FDA 483 - Wells Pharma of Houston LLC - December 14, 2022

During an FDA inspection conducted from November 16 to December 14, 2022, Wells Pharma of Houston LLC, an outsourcing facility, received a Form FDA 483 detailing significant observations regarding its manufacturing practices. The inspection highlighted three primary areas needing immediate attention to ensure regulatory compliance and product quality.

First, the company's electronic building monitoring system, vital for controlling temperature, humidity, and differential pressure in sterile and non-sterile drug production areas, was inadequately validated. The initial validation lacked proper documentation for differential pressure, and revalidation was delayed, raising concerns about environmental control integrity for distributed sterile products.

Second, facility construction issues were noted, specifically a 0.5-inch gap at the bottom of an ISO 8 pass-through door. This gap presents a potential contamination pathway, allowing lower quality air to compromise the higher quality ISO 7 Cleanroom where aseptic processing takes place.

Lastly, the quality control unit's written procedures were found insufficient. Procedures for monitoring environmental conditions lacked clearly defined differential pressure specifications, as well as alert and action limits for critical classified areas like the ISO 8 Anteroom, ISO 8 Gowning Room, and ISO 7 Cleanroom. These deficiencies are crucial for maintaining controlled environments in sterile drug manufacturing. Wells Pharma of Houston LLC is expected to develop and implement comprehensive corrective actions to address these observations.